Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spit test could slash endometriosis diagnosis time

NCT ID NCT05244668

Diagnosis Sponsor: ZIWIG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new saliva-based test to diagnose endometriosis, a painful condition that often takes years to identify. Researchers collected saliva from over 1,100 women with confirmed or suspected endometriosis to see if the test could accurately detect the disease. The goal is to provide a simple, non-invasive tool that speeds up diagnosis and improves care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
salivary miRNA signature test
What this could lead to
If successful, this saliva test could provide a quick, non-invasive way to diagnose endometriosis, shortening the years-long delay many women face.
What could go wrong
This is a validation study, not a treatment trial. The test may not meet the high accuracy targets, and results may not apply to all populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,140 people

The number who actually took part.

Started

Dec 2021

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population is made up of women aged 18 to 43 years with a formal diagnosis of endometriosis or suspected endometriosis. The patients concerned by the study are already receiving either medical (MAP) or surgical care in a department of Obstetrics and Reproductive Medicine. All these patients already benefit from validation of therapeutic indications in a multidisciplinary consultation meeting (medical-surgical or fertility RCP). The patients concerned by the study are managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic examinations (imaging or biology) necessary according to the context, which are carried out according to the recommendations of the HAS.

Ages

18 to 43 years

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient aged between 18 and 43 years, * Patient having dated and signed the consent form, * Patient affiliated to the French health system, * Patient with pelvic MRI and/or pelvic ultrasound, * Patient from one of the 3 study populations: * Patient with a formal endometriosis diagnosed by clinical examination and imaging AND an indication for specialised endometriosis follow-up or medically assisted procreation (MAP) or surgery validated by RCP (in routine care); * Patient with suspected endometriosis for whom the diagnosis is the source of a discrepancy between clinical and radiological data AND a surgical indication validated by RCP (in routine care); * Patient with a gynaecological indication for surgery of the small pelvis by laparoscopy or laparoscopy validated in RCP (in routine care) AND symptoms suggestive of endometriosis (dysmenorrhoea, ....)(1). Exclusion Criteria: * Patient with recurrence of deep endometriosis (excluding endometrioma), * Patient with endometriosis of the torus and/or utero-sacral ligaments without indication for surgery, * Patient with parietal endometriosis alone without indication for surgery, * Patient with adenomyosis alone on imaging without indication for surgery, * Patient with gynaecological infection requiring surgical management, * Pregnant patient, * Patient infected with the human immunodeficiency virus (HIV), * Patient with significant difficulties in reading or writing the French language, * Patient with a personal history of cancer, * Patient unable to comply with study and/or follow-up procedures, * Patient who has objected to the collection of her data. * Patient participating in another clinical research study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometriosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometriosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometriosis

Contacts and locations

Locations

  • CH Bastia

    Bastia, 20600, France

  • CHU Angers

    Angers, 49933, France

  • CHU Québec

    Québec, Canada

  • CHU Rennes

    Rennes, 35000, France

  • CHU Rouen

    Bois-Guillaume, Seine-Maritime, 76230, France

  • CHU Strasbourg - Hôpital Hautepierre

    Strasbourg, Alsace, 67200, France

  • CHU Tenons

    Paris, 75020, France

  • CHU Toulouse - Hôpital Rangueil

    Toulouse, Haute Garonne, 31059, France

  • CHU de Caen

    Caen, Calvados, 14000, France

  • Cabinet de Gynécologie Médicale

    Lyon, Rhône, 69002, France

  • Centre d'imagerie Manin Crimée

    Paris, 75019, France

  • Centre médical des Pyramides

    Maurepas, Yvelines, 78310, France

  • Clinique La Sagesse

    Rennes, Ille Et Vilaine, 35000, France

  • Clinique Pasteur

    Toulouse, Haute-Garonne, 31300, France

  • Clinique Tivoli

    Bordeaux, Gironde, 33000, France

  • Groupe Hospitalier Saint Josef

    Paris, 75014, France

  • HCL

    Lyon, 69000, France

  • Hôpital BICETRE

    Le Kremlin-Bicêtre, Val De Marne, 94275, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.